Paul M McKie

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. doi request reprint Defining high-sensitivity cardiac troponin concentrations in the community
    Paul M McKie
    Cardiorenal Research Laboratory, Mayo Clinic and Foundation, Rochester, MN 55902, USA
    Clin Chem 59:1099-107. 2013
  2. doi request reprint CD-NP: an innovative designer natriuretic peptide activator of particulate guanylyl cyclase receptors for cardiorenal disease
    Paul M McKie
    Cardiorenal Research Laboratory, Division of Cardiovascular Disease, Mayo Clinic and Foundation, 200 First Street Southwest, Rochester, MN 55905, USA
    Curr Heart Fail Rep 7:93-9. 2010
  3. doi request reprint M-atrial natriuretic peptide: a novel antihypertensive protein therapy
    Paul M McKie
    Mayo Clinic, Division of Cardiovascular Diseases, Rochester, MN 55905, USA
    Curr Hypertens Rep 14:62-9. 2012
  4. doi request reprint A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension
    Paul M McKie
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Hypertension 56:1152-9. 2010
  5. pmc The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects
    Paul M McKie
    Cardiorenal Research Laboratory, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    J Am Coll Cardiol 55:2140-7. 2010
  6. pmc A human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressure-lowering, renal-enhancing, and aldosterone-suppressing actions
    Paul M McKie
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    J Am Coll Cardiol 54:1024-32. 2009
  7. pmc Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure
    Paul M McKie
    Cardiorenal Research Laboratory, Mayo Clinic and Foundation, Rochester, MN, USA
    Hypertension 47:874-80. 2006
  8. ncbi request reprint B-type natriuretic peptide as a biomarker beyond heart failure: speculations and opportunities
    Paul M McKie
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 80:1029-36. 2005
  9. pmc Predictive utility of atrial, N-terminal pro-atrial, and N-terminal pro-B-type natriuretic peptides for mortality and cardiovascular events in the general community: a 9-year follow-up study
    Paul M McKie
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 86:1154-60. 2011
  10. pmc CD-NP: a novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heart
    Fernando L Martin
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, United States of America
    PLoS ONE 7:e52422. 2012

Detail Information

Publications23

  1. doi request reprint Defining high-sensitivity cardiac troponin concentrations in the community
    Paul M McKie
    Cardiorenal Research Laboratory, Mayo Clinic and Foundation, Rochester, MN 55902, USA
    Clin Chem 59:1099-107. 2013
    ..Therefore, our objective was to define hs-cTnI reference values and determinants in the general community, in a healthy reference cohort, and in subsets with diseases...
  2. doi request reprint CD-NP: an innovative designer natriuretic peptide activator of particulate guanylyl cyclase receptors for cardiorenal disease
    Paul M McKie
    Cardiorenal Research Laboratory, Division of Cardiovascular Disease, Mayo Clinic and Foundation, 200 First Street Southwest, Rochester, MN 55905, USA
    Curr Heart Fail Rep 7:93-9. 2010
    ..Thus, CD-NP has emerged as an appealing novel therapeutic strategy for heart failure. The endogenous NP system, the development rationale for CD-NP, as well as in vitro, animal, and human studies and future directions will be reviewed...
  3. doi request reprint M-atrial natriuretic peptide: a novel antihypertensive protein therapy
    Paul M McKie
    Mayo Clinic, Division of Cardiovascular Diseases, Rochester, MN 55905, USA
    Curr Hypertens Rep 14:62-9. 2012
    ..M-ANP currently is heading into clinical testing, which may advance this novel strategy for human hypertension...
  4. doi request reprint A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension
    Paul M McKie
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Hypertension 56:1152-9. 2010
    ..These results suggest that M-ANP, which is more potent than ANP in normal canines, has potent blood pressure lowering and renal enhancing properties and may, therefore, serve as an ANP based therapeutic for acute hypertension...
  5. pmc The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects
    Paul M McKie
    Cardiorenal Research Laboratory, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    J Am Coll Cardiol 55:2140-7. 2010
    ....
  6. pmc A human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressure-lowering, renal-enhancing, and aldosterone-suppressing actions
    Paul M McKie
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    J Am Coll Cardiol 54:1024-32. 2009
    ..We sought to determine the physiologic actions and potential therapeutic applications of mutant atrial natriuretic peptide (mANP)...
  7. pmc Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure
    Paul M McKie
    Cardiorenal Research Laboratory, Mayo Clinic and Foundation, Rochester, MN, USA
    Hypertension 47:874-80. 2006
    ....
  8. ncbi request reprint B-type natriuretic peptide as a biomarker beyond heart failure: speculations and opportunities
    Paul M McKie
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 80:1029-36. 2005
    ....
  9. pmc Predictive utility of atrial, N-terminal pro-atrial, and N-terminal pro-B-type natriuretic peptides for mortality and cardiovascular events in the general community: a 9-year follow-up study
    Paul M McKie
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 86:1154-60. 2011
    ....
  10. pmc CD-NP: a novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heart
    Fernando L Martin
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, United States of America
    PLoS ONE 7:e52422. 2012
    ..Taken together, this novel dual GC receptor activator may represent an innovative anti-fibrotic therapeutic agent...
  11. pmc Differential expression of the pro-natriuretic peptide convertases corin and furin in experimental heart failure and atrial fibrosis
    Tomoko Ichiki
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Am J Physiol Regul Integr Comp Physiol 304:R102-9. 2013
    ..Selective changes of these NP convertases may have significance in the regulation of pro-NP processing and atrial remodeling in early stage HF...
  12. pmc A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community
    Valentina Cannone
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Am Coll Cardiol 58:629-36. 2011
    ..We sought to define the cardiometabolic phenotype associated with rs5068, a genetic variant of the atrial natriuretic peptide (ANP) gene...
  13. doi request reprint Corin is present in the normal human heart, kidney, and blood, with pro-B-type natriuretic peptide processing in the circulation
    Tomoko Ichiki
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, MN 55905, USA
    Clin Chem 57:40-7. 2011
    ..The corin gene is expressed in the human heart and kidney, but corin protein expression in the heart, kidney, and circulation, along with whether proBNP is processed by circulating corin, remains unknown...
  14. pmc Cardiac micro-computed tomography imaging of the aging coronary vasculature
    S Jeson Sangaralingham
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Circ Cardiovasc Imaging 5:518-24. 2012
    ....
  15. pmc Experimental mild renal insufficiency mediates early cardiac apoptosis, fibrosis, and diastolic dysfunction: a kidney-heart connection
    Fernando L Martin
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, 200 First St, SW, Rochester, MN 55905, USA
    Am J Physiol Regul Integr Comp Physiol 302:R292-9. 2012
    ..Thus, these studies importantly advance the concept of a kidney-heart connection in the control of myocardial structure and function...
  16. pmc Urinary C-type natriuretic peptide excretion: a potential novel biomarker for renal fibrosis during aging
    S Jeson Sangaralingham
    Cardiorenal Research Laboratory, Div of Cardiovascular Diseases, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Am J Physiol Renal Physiol 301:F943-52. 2011
    ....
  17. doi request reprint The aging heart, myocardial fibrosis, and its relationship to circulating C-type natriuretic Peptide
    S Jeson Sangaralingham
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Hypertension 57:201-7. 2011
    ..Together, these studies provide new insights into myocardial aging and the relationship to the antifibrotic and antiproliferative peptide CNP...
  18. ncbi request reprint Oral human brain natriuretic peptide activates cyclic guanosine 3',5'-monophosphate and decreases mean arterial pressure
    Alessandro Cataliotti
    Department of Physiology and Internal Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Circulation 112:836-40. 2005
    ..We hypothesized that novel oral conjugated hBNP (CONJ-hBNP) increases plasma hBNP, activates cGMP, and reduces mean arterial pressure (MAP)...
  19. pmc Impaired natriuretic and renal endocrine response to acute volume expansion in pre-clinical systolic and diastolic dysfunction
    Paul M McKie
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    J Am Coll Cardiol 58:2095-103. 2011
    ..We further hypothesized that exogenous B-type natriuretic peptide (BNP) could rescue an impaired natriuretic response in PSD and PDD...
  20. pmc M-atrial natriuretic peptide and nitroglycerin in a canine model of experimental acute hypertensive heart failure: differential actions of 2 cGMP activating therapeutics
    Paul M McKie
    Cardiorenal Research Laboratory, Mayo Clinic, Rochester, MN
    J Am Heart Assoc 3:e000206. 2014
    ....
  21. ncbi request reprint Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy
    Paola Belluardo
    Cardiorenal Research Laboratory, 200 First St, SW, Rochester, MN 55905, USA
    Am J Physiol Heart Circ Physiol 291:H1529-35. 2006
    ..The later activation of both forms of BNP may be a late compensatory effect, because it correlates with severity of HTN rather than cardiac hypertrophy/remodeling...
  22. pmc Rationale and design of a randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy of B-type natriuretic peptide for the preservation of left ventricular function after anterior myocardial infarction
    S Jeson Sangaralingham
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Card Fail 19:533-9. 2013
    ..006 μg kg(-1) min(-1) suppressed plasma aldosterone, reduced cardiac dilatation, and improved left ventricular (LV) ejection fraction (LVEF) at 1 month compared with baseline...
  23. doi request reprint B-type natriuretic peptide and survival in hypertrophic cardiomyopathy
    Jeffrey B Geske
    Department of Internal Medicine, Division of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Am Coll Cardiol 61:2456-60. 2013
    ..The aim of this study was to determine the relationship between B-type natriuretic peptide (BNP) and survival in patients with hypertrophic cardiomyopathy...